News
AtriCure Q2 2024 Earnings: EPS Misses Expectations
AtriCure (NASDAQ:ATRC) Second Quarter 2024 Results
Main financial results
-
Revenue: $116.3 million (up 15% from Q2 2023).
-
Net loss: US$8.01 million (loss widened by 56% compared to Q2 2023).
-
Loss of $0.17 per share (still worse than the $0.11 loss in Q2 2023).
earnings-and-revenue-growth
All numbers shown in the chart above are for the trailing 12 month period (TTM)
AtriCure EPS does not meet expectations
Revenue was in line with analysts’ estimates. Earnings per share (EPS) missed analysts’ estimates by 1.3%.
Looking ahead, revenue is expected to grow 13% per year on average over the next 3 years, compared to a forecast growth of 8.2% for the US medical device industry.
Performance of the American medical equipment industry.
The company’s shares are down 8.3% from last week.
Risk analysis
What about risks? Every company has them, and we identify them 2 warning signs for AtriCure you should know about.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts using only an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take into account your objectives or financial situation. Our aim is to bring you long-term focused analysis, driven by fundamental data. Please note that our analysis may not take into account the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, send an email editorial-team@simplywallst.com